Genomics England is a company with its registered office in London, United Kingdom, that works with the NHS to advance the use of genomic healthcare and research in Britain. The Secretary of State is its only shareholder.
Subscribe to see Genomics England’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Genomics England is a biotech company headquartered in United Kingdom, founded in 2013. Xcout recorded 33 job postings from Genomics England in the last 90 days, naming tools such as GitLab, Jira, Confluence.
Xcout recorded 33 job postings from Genomics England in the last 90 days, from a hiring record Xcout has kept since May 2026.
The weekly hiring trend, the roles and locations behind it — see Genomics England's hiring signals →
A few of Genomics England's closest competitors — see the full list of competitors and alternatives →
Source BioScience is a UK-based laboratory services company providing genomics, DNA sequencing, molecular diagnostics, and pathology-related testing. It serves pharmaceutical and biotechnology companies, healthcare organizations, research institutions, and other life-science customers.
Oxford Nanopore Technologies plc is a UK-based company which develops and sells nanopore sequencing products for the direct, electronic analysis of single molecules. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
Genome Medical provides telehealth-enabled genetic services, offering expert genetic counseling, genetic test ordering, and clinical trial matching for patients and families. The company also partners with healthcare providers, health systems, and life sciences organizations to expand access to genetics care and improve rare disease diagnosis and management.
Enhanced Genomics Ltd. is a functional genomics company headquartered in Cambridge, United Kingdom. The firm utilizes its proprietary 3D multi-omics genomics technology to uncover causal biology behind genetic variation and transform drug target discovery.
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.